Brain

Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition

– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory and neuroprotective properties through modulation...

CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group

Unveiling the Potential Breakthrough - Activating Stem Cells to Delay and Reduce Dementia and Depression RiskLOS ANGELES, CA / ACCESSWIRE...

Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.

Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE)...

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Significant Reduction of Amyloid Beta Biomarkers of Alzheimer’s PathologyNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp....

Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference

-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science...

Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV

PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary...

Baylor Genetics Announces Neurodevelopmental Disorders Test Panel to Help Healthcare Providers Diagnose Patients with Intellectual Disabilities or Developmental Delays

New Test Analyzes Highly Curated Set of 236 Genes Most Associated with Autism Spectrum Disorder, Intellectual Disabilities, and Developmental Delay.HOUSTON,...

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Treatment Could Help Restore Brain Functions Lost in Many Neurogenerative DisordersSAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc.,...

error: Content is protected !!